Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin B - Solstice Neurosciences/US WorldMeds

Drug Profile

Botulinum toxin B - Solstice Neurosciences/US WorldMeds

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 31 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sialorrhoea; Torticollis

Most Recent Events

  • 23 Sep 2019 US WorldMeds plans a phase II/III trial for Muscle spasticity (SN-SPAS-202; NCT04099667)
  • 27 Aug 2019 Launched for Sialorrhoea (In adults) in USA (Intraglandular)
  • 26 Aug 2019 Registered for Sialorrhoea (In adults) in USA (Intraglandular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top